Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first

A U.S. biotech company is listing in Hong Kong instead of Wall Street, per CNBC. The move follows a broader trend: biotech firms globally are increasingly drawn to Hong Kong for its investor base and proximity to Chinese pharmaceutical partners.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton